On July 27, the U.S. Food and Drug Administration (FDA) officially approved the once-daily extended-release capsule Simtriyo (centanafadine), developed by Japan's Otsuka Pharmaceutical, for the treatment of attention deficit hyperactivity disorder (ADHD) in patients aged six and older.

This drug is the world's first approved norepinephrine, dopamine, and serotonin reuptake inhibitor (NDSRI). In terms of clinical performance and mechanism of action, Simtriyo works by inhibiting the reuptake of these neurotransmitters, thereby increasing their availability in neural pathways.

Clinical data from four Phase III trials involving both adults and children demonstrated that the drug significantly improved core ADHD symptoms. Recently released Phase IIIb data further confirmed its notable efficacy in ADHD patients with comorbid anxiety. Researchers from NYU Grossman School of Medicine noted that this new drug introduces a novel mechanism of action, offering clinicians and patients a wider range of treatment options for personalized care. According to trial records, common adverse reactions mainly include decreased appetite, nausea, rash, and headache.

Regarding the subsequent commercialization process, analysts at Jefferies emphasized that the drug's market competitiveness will largely depend on the scheduling classification by the U.S. Drug Enforcement Administration (DEA). Since the FDA has classified Simtriyo as a stimulant with dopaminergic effects, it must undergo a standard DEA review process, lasting up to three months, before it can be officially sold in the U.S. If it receives a more lenient scheduling rating, it could establish a clear competitive advantage in the crowded ADHD market.

ADHD is a chronic neurodevelopmental disorder characterized by difficulty concentrating and impulse control issues. According to the U.S. Centers for Disease Control and Prevention (CDC), approximately 7 million children and 15.5 million adults in the U.S. are affected by this condition. Currently, traditional stimulant medications are the primary treatment, but they often lead to frequent discontinuation or switching due to waning efficacy, side effects, or changing life demands, creating an urgent market need for drugs with novel mechanisms of action.

Otsuka acquired the development rights to this drug after purchasing Neurovance in 2017. This new drug approval marks a substantial expansion of Otsuka's business footprint in the central nervous system (CNS) field, extending its product line from existing treatments for conditions like schizophrenia to the broader neurodevelopmental disorder market. Based on the large potential patient base, Otsuka projects that the drug's peak sales will exceed 100 billion yen.